TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Tesla Lead
Play
INVESTING

Buy-the-Dip Candidates in the Stock Market: Tesla, Palantir

  • By Danny Peterson
  • Feb 17, 2021 8:13 AM EST
Tesla Lead
INVESTING

Buy-the-Dip Candidates in the Stock Market: Tesla, Palantir

  • By Danny Peterson
  • Feb 17, 2021 8:13 AM EST
PRESS RELEASES

Astellas And Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage Of PADCEV® (enfortumab Vedotin-ejfv) In Patients With Previously Treated Advanced Urothelial Cancer

  • By PR Newswire
  • Feb 12, 2021 2:15 PM EST
Stock Futures Rise After U.S. Jobs Growth Is Higher Than Expected
MARKETS

Bumble, Tilray, Disney, PepsiCo and Pinterest - 5 Things You Must Know Thursday

  • By Joseph Woelfel
  • Feb 11, 2021 6:29 AM EST
PRESS RELEASES

Seagen And Genmab Submit Tisotumab Vedotin Biologics License Application To The U.S. FDA For Patients With Recurrent Or Metastatic Cervical Cancer

  • By Business Wire
  • Feb 10, 2021 4:05 PM EST
PRESS RELEASES

Seagen To Host Conference Call And Webcast Discussion Of Fourth Quarter And Full Year 2020 Financial Results On February 11, 2021

  • By Business Wire
  • Jan 7, 2021 8:00 AM EST
Moderna Lead
INVESTING

5 Worst Stocks in the Nasdaq on Wednesday: Moderna Slides Again

  • By Fatma Khaled
  • Dec 30, 2020 6:15 PM EST
Zoom Video Jumps as Baird Initiates Coverage With Outperform Rating
INVESTING

7 Worst Stocks in the Nasdaq on Wednesday: Zoom Sinks

  • By Fatma Khaled
  • Dec 23, 2020 4:44 PM EST
PRESS RELEASES

Seagen To Present At The J.P. Morgan Healthcare Conference

  • By Business Wire
  • Dec 16, 2020 8:00 AM EST
PRESS RELEASES

Alpine Immune Sciences Appoints Natasha Hernday To Board Of Directors

  • By Business Wire
  • Dec 11, 2020 8:00 AM EST
PRESS RELEASES

Seagen Announces Positive CHMP Opinion For TUKYSA® (tucatinib) For The Treatment Of Patients With Locally Advanced Or Metastatic HER2-Positive Breast Cancer

  • By Business Wire
  • Dec 11, 2020 7:23 AM EST
Disney Lead
Video

Jim Cramer Picks Stocks You Should Buy, Sell or Hold

  • Nov 16, 2020 9:02 AM EST
PRESS RELEASES

Seagen To Host Virtual R&D Day On November 16, 2020

  • By Business Wire
  • Nov 2, 2020 8:00 AM EST
PRESS RELEASES

Seagen Announces Closing Of $1.0 Billion Stock Sale To Merck

  • By Business Wire
  • Oct 28, 2020 8:00 AM EDT
PRESS RELEASES

Seagen To Host Conference Call And Webcast Discussion Of Third Quarter 2020 Financial Results On October 29, 2020

  • By Business Wire
  • Oct 13, 2020 8:00 AM EDT
PRESS RELEASES

Seagen And Astellas Announce Positive Topline Results From Second Cohort Of Patients In Phase 2 Pivotal Trial Of PADCEV® (enfortumab Vedotin-ejfv) In Advanced Urothelial Cancer

  • By Business Wire
  • Oct 12, 2020 6:45 AM EDT
PRESS RELEASES

Astellas And Seagen Announce Positive Topline Results From Second Cohort Of Patients In Phase 2 Pivotal Trial Of PADCEV® (enfortumab Vedotin-ejfv) In Advanced Urothelial Cancer

  • By PR Newswire
  • Oct 12, 2020 6:45 AM EDT
PRESS RELEASES

Seattle Genetics And Genmab Present Data From Tisotumab Vedotin InnovaTV 204 Pivotal Trial In Recurrent Or Metastatic Cervical Cancer At ESMO Virtual Congress 2020

  • By Business Wire
  • Sep 21, 2020 10:20 AM EDT
Sell Unitedhealth
INVESTING

5 Best Stocks in the Dow This Past Week

  • By Vidhi Choudhary
  • Sep 21, 2020 11:22 AM EDT
PRESS RELEASES

PADCEV® (enfortumab Vedotin-ejfv) (Photo: Business Wire)

  • By Business Wire
  • Sep 18, 2020 6:45 AM EDT
PRESS RELEASES

Astellas And Seattle Genetics Announce PADCEV® (enfortumab Vedotin-ejfv) Significantly Improved Overall Survival In Phase 3 Trial In Previously Treated Locally Advanced Or Metastatic Urothelial Cancer

  • By PR Newswire
  • Sep 18, 2020 6:45 AM EDT
New York Stock Exchange Lead
JIM CRAMER

Still Undervalued: Cramer's 'Mad Money' Recap (Monday 9/14/20)

  • By Scott Rutt
  • Sep 14, 2020 9:00 PM EDT
Activist Investor to Block Partnership of Immunomedics and Seattle Genetics
INVESTING

Immunomedics, Scientific Games: 5 Top Gainers for Monday

  • By Rob Lenihan
  • Sep 14, 2020 4:21 PM EDT
Jim Cramer Katherine Ross Lead
Video

Jim Cramer: Nvidia's Going to Surpass Intel

  • Sep 14, 2020 11:30 AM EDT
Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly
INVESTING

Merck Takes Seattle Genetics Stake, Plans Cancer-Drug Venture

  • By Dan Weil
  • Sep 14, 2020 9:38 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.